Anderson James¹, Müller Johann², Thompson Emily³,Schneider Lukas⁴, Becker Sophie⁵, Clarke William⁶, Wagner Anna⁷
ABSTRACT:
Background: Breast cancer heterogeneity necessitates biomarkers beyond conventional histopathology. Multi-omics approaches combining epigenetic, proteomic, and metabolomic data offer unprecedented resolution for subtyping and treatment personalization. Methods and Results: We synthesize evidence from 120 studies on DNA methylation signatures, protein panels (e.g., HER2-phosphoproteomics), and metabolic rewiring (e.g., oncometabolites). Conclusion: Integrated omics biomarkers improve diagnostic accuracy by 30-50% in trials but require standardization for clinical adoption.